Spots Global Cancer Trial Database for A Study for Patients With Secondary Progressive Multiple Sclerosis
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Study for Patients With Secondary Progressive Multiple Sclerosis
Official Title: A Double-Blind, Placebo Controlled Multicentre Study To Evaluate The Efficacy And Safety Of MBP8298 In Subjects With Secondary Progressive Multiple Sclerosis
Study ID: NCT00869726
Conditions
Study Description
Brief Summary: The purpose of this study is to determine whether MBP8298 is effective and safe in the treatment secondary progressive multiple sclerosis. Dirucotide is generic name for MBP8298.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
St. Michaels Hospital, Toronto, Ontario, Canada
Copenhagen University Hospital, Kobenhavn, , Denmark
West Tallinn Central Hospital, Tallinn, , Estonia
Terveystalo Turku Kuvantaminen, Turku, , Finland
Heinrich Heine Universitaets, Duesseldorf, , Germany
Vecmilgravis Hospital, Riga, , Latvia
Maaslandziekenhuis, Sittard, , Netherlands
Hospital Duran I Reynals, Barcelona, , Spain
Karolinska Universitetssjukhus, Stockholm, , Sweden
Walton Hospital, Liverpool, , United Kingdom
Contact Details
Name: Call 1-877-CTLILLY (1-877-285-4559) or 317-615-4559 Mon-Fri 9am-5pm Eastern time (UTC/GMT - 5 hours, EST)
Affiliation: Eli Lilly and Company
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
